AstraZeneca’s Tagrisso plus Orpathys extends survival in lung cancer
AstraZeneca has discontinued a Phase 3 study of one of its cancer drugs. According to Endpoints News, this is the latest in a series of setbacks for the drugmaker.
The study in question was the SAFFRON Phase III trial, which was investigating the combination of Tagrisso (osimertinib) and Orpathys (savolitinib) for patients with EGFR-mutated non-small cell lung cancer.
Investing.com reports that the trial showed statistically significant improvements in progression-free survival and overall survival compared to platinum-based chemotherapy. However, despite these results, AstraZeneca decided to end the study.
Brief written by urgent.news from Endpoints News, Investing.com — 2 reports on this story. Machine-written — may contain errors; check the original before relying on it.
Also reported by 3 other outlets
- AstraZeneca touts separate late-stage lung cancer wins with Tagrisso, Enhertu endpoints.news
- AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer biopharmadive.com
- AstraZeneca hit by lung cancer drug setback: Pharma giant halts trials of experimental Volrustomig treatment thisismoney.co.uk
